

# Xellia Pharmaceuticals

---



Xellia Pharmaceuticals is a specialty pharmaceutical company developing, manufacturing and commercializing anti-infective treatments against serious and often life-threatening bacterial and fungal infections. Xellia is a world-leading trusted supplier of several important established anti-infective drugs, comprising active pharmaceutical ingredients as well as finished dosage forms, where the majority are injectable drug products. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1800 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers.

Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics' sector.

Xellia is the leading supplier of important anti-infectives vancomycin and colistimethate sodium (CMS). Our success and strong market position is built on more than 115 years' of pharmaceutical industry experience.


Xellia Pharmaceuticals' focus its R&D investments within inhalable and injectable product technologies as we are committed to researching solutions, which improve patients' quality of life.

Supplying products to more than 70 countries worldwide and with more than 500 customers internationally, Xellia Pharmaceuticals places a high regard on maintaining strong relationships with its customers.

Our sales team serves as the first point of contact for customers, ensuring fast and

accurate delivery of product information; through managing orders to delivery. Xellia Pharmaceuticals' Global Technical Support team serves as the main point of contact for customers to provide them with specialized support for all technical matters that may be associated with market entry and launch of products.

Working collaboratively with the sales team and cross-functionally with Xellia's internal departments at all sites, Xellia Pharmaceuticals is dedicated to providing reliable outstanding service to its customers at all times.



# Active Pharmaceutical Ingredients and Finished Dosage Forms

---

## APIs      FDFs

Amphotericin B	<b>Bacitracin vials</b> 50.000 units
Bacitracin	<b>Colistimethate sodium dry-filled vials</b> 1 miu, 2 miu
Bacitracin zinc	<b>Colistimethate sodium lyophilized vials</b> 150 mg
Colistimethate sodium	<b>Daptomycin* vials</b> 350 mg, 500 mg
Colistin sulfate	<b>Micafungin* vials</b> 50 mg, 100 mg
Daptomycin*	<b>Polymyxin B vials</b> 500.000 units
Gramicidin	<b>Vancomycin Injection</b> ready to use bags 500 mg, 750 mg, 1 g, 1.25 g, 1.5 g, 1.75 g, 2 g
Polymyxin B sulfate	<b>Vancomycin HCl vials</b> 0.5 g, 1 g, 5 g, 10 g
Tobramycin sulfate	<b>Voriconazole vials</b> 200 mg
Tyrothricin	<i>*Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement.</i>
Vancomycin hydrochloride	

---

**INTERNATIONAL SALES OFFICE:** Xellia Pharmaceuticals ApS, Copenhagen, Denmark  
Tel: [+45 32 64 55 00](tel:+4532645500) E-mail: [sales@xellia.com](mailto:sales@xellia.com)

**LOCAL SALES OFFICES AND GLOBAL TECHNICAL SUPPORT:**  
[www.xellia.com/contact](http://www.xellia.com/contact)

A company owned by Novo Holdings A/S  
[www.xellia.com](http://www.xellia.com)